Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204938) titled 'A Long-Term Study of Navenibart in Participants With Hereditary Angioedema' on Sept. 30.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Astria Therapeutics, Inc.

Condition: Hereditary Angioedema (HAE)

Intervention: Drug: navenibart

Recruitment Status: Recruiting

Phase: Phase 3

Date of First Enrollment: October 2025

Target Sample Size: 145

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07204938

Published by HT Digital ...